Document is current

Any future updates will be listed below

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

Crossref DOI link: https://doi.org/10.1038/s41392-026-02720-6

Published Online: 2026-05-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark